Skip to main content

Table 3 Cutolo’s NVC patterns, CSURI and VEGF levels in the SSc cohort (n = 44)

From: Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvement

  Early pattern Active pattern Late pattern CSURI VEGF-A
Females vs males 6 (14.3 %) vs 0 (0 %) 18 (42.9 %) vs 2 (100 %) 18 (42.9 %) vs 0 (0 %) 9.6 (0.14–80.0) vs 23.2 (19.0–27.5) 0.49 (0.02–3.05) vs 0.25 (0.11–0.38)
Diffuse vs limited 1 (10 %) vs 5 (14.7 %) 5 (50.0 %) vs 15 (44.1 %) 4 (40 %) vs 14 (41.7 %) 9.1 (2.4–50.5) vs 10.5 (0.14–80.0) 0.42 (0.11–3.05) vs 0.49 (0.02–0.07)
Anti-Scl70 vs ACA 0 (0 %) vs 2 (9.1 %) 5 (41.7 %) vs 11 (50 %) 7 (58.3 %) vs 10 (45.4 %) 11.4 (3.6–20.7) vs 11.9 (0.51–80.0) 0.46 (0.13–1.14) vs 0.49 (0.02–1.70)
Anti-Scl70 vs others 0 (0 %) vs 4 (40 %) 5 (41.7 %) vs 4 (40 %) 7 (58.3 %) vs 1 (10 %) 11.4 (2.4–50.5) vs 9.2 (0.14–27.5) 0.46 (0.13–1.14) vs 0.43 (0.02–3.05)
ACA vs others 2 (9.1 %) vs 4 (40 %) 11 (50 %) vs 4 (40 %) 10 (45.4 %) vs 1 (10 %) 11.9 (0.51–80.0) vs 9.2 (0.14–27.5) 0.49 (0.02–1.7) vs 0.43 (0.11–3.05)
No ulcers vs ulcers 3 (10.3 %) vs 2 (13.3 %) 13 (29.5 %) vs 7 (46.7 %) 12 (41.4 %) vs 6 (40 %) 11.9 (0.14–68.7) vs 9.1 (0.51–80.0) 0.47 (0.02–3.05) vs 0.50 (0.11–1.14)
No GE vs GE 2 (22.2 %) vs 4 (11.4 %) 4 (44.4 %) vs 16(45.7 %) 3 (33.3 %) vs 15 (42.5 %) 7.0 (0.51–68.7) vs 12.0 (0.14–80.0) 0.37 (0.13–1.0) vs 0.49 (0.02–3.05)
sPAP < 45
vs > 45 mmHg
6 (14.6 %) vs 0 (0 %) 20 (48.8 %) vs 0 (0 %) 17 (41.4 %) vs 3 (100 %)* 9.9 (0.14–80.0) vs 13 (3.9–15.1) 0.49 (0.02–3.05) vs 0.28 (0.21–0.35)
DLCO < 50 % vs > 50 % 0 (0 %) vs 6 (15.8 %) 2 (33.3 %) vs 18 (47.3 %) 4 (66.6 %) vs 11 (28.9 %) 5.9 (3.9–13.7) vs 11.3 (0.14–80.0) 0.48 (0.28–1.14) vs 0.49 (0.02–3.05)
FVC < 80 % vs > 80 % 0 (0) vs 6 (16.2 %) 3 (42.8 %) vs 17 (45.9 %) 4 (57.1 %) vs 14 (37.8 %) 9.1 (0.14–80.0) vs 13 (3.3–27.5) 0.54 (0.02–3.05) vs 0.38 (0.11–1.0)
No honeycombing vs honeycombing 5 (12.8 %) vs 1 (20 %) 19 (48.7 %) vs 1 (20 %) 15 (38.4 %) vs 3 (60 %)* 5.9 (0.14–80.0) vs 11.8 (5.1–15.1) 0.34 (0.02–3.05) vs 0.68 (0.28–1.14)
Skin score < 14 vs > 14 6 (16.2 %) vs 0 (0 %) 16 (43.2 %) vs 4 (57.1 %) 16 (43.2 %) vs 3 (42.8 %) 10.9 (0.14–80.0) vs 5.5 (2.1–68.7) 0.46 (0.02–1.7) vs 0.52 (0.11–3.05)
No iloprost vs iloprost 3 (15.8 %) vs 3 (12 %) 11 (57.9 %) vs 9 (36 %) 5 (26.3 %) vs 13 (52 %)* 10.5 (0.51–68.7) vs 9.2 (0.14–80.0) 0.38 (0.02–3.05) vs 0.49 (0.13–1.70)
No bosentan vs bosentan 6 (16.2 %) vs 0 (0 %) 19 (51.3 %) vs 1 (14.2 %) 12 (32.4 %) vs 6 (85.7 %)* 10.9 (0.14–80.0) vs 8.3 (3.9–22.3) 0.50 (0.02–3.05) vs 0.28 (0.21–0.58)
Early pattern vs others 4.2 (0.14–11.3) vs 11.2 (0.51–80.0) 0.63 (0.02–0.77) vs 0.39 (0.11–3.05)
Active pattern vs others 5.9 (1.4–68.7) vs 12.1 (0.14–80.0) 0.48 (0.11–3.05) vs 0.43 (0.02–1.07)
Late pattern vs others 13.7 (0.51–80.0) vs 5.9 (0.14–68.7)* 0.35 (0.21–1.70) vs 0.58 (0.02–3.05)
VEGF-A < 0.8U vs > 0.8U 5 (13.5 %) vs 1 (14.3 %) 16 (43.2 %) vs 4 (57.1 %) 16 (43.2 %) vs 2 (28.5 %) 10.2 (0.14–80.0) vs 9.0 (3.3–13.7)
CSURI > 2.94 vs < 2.94 4 (11.1 %) vs 2 (25 %) 15 (41.6 %) vs 5 (62.5 %) 17 (47.2 %) vs 1 (12.5 %)* 0.46 (0.02–3.05) vs 0.58 (0.13-0.71)
  1. anti-Scl70 anti-topoisomerase I, CSURI capillaroscopic skin ulcer risk index, D diffuse, DLCO carbon monoxide diffusing capacity, FVC forced vital capacity, L limited, GE gastro-esophageal, NVC nailfold videocapillaroscopy, VEGF-A vascular endothelial growth factor A, sPAP systolic pulmonary artery pressure on echocardiography, SSc systemic sclerosis; vs: versus, ACA anti-centromere
  2. * p < 0.05
\